JTCS Speed Up Your Browser
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Faisal G. Bakaeen
Dawn E. Jaroszewski
David C. Rice
Ara A. Vaporciyan
Robert Benjamin
Shanda Blackmon
Michael J. Reardon
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Bakaeen, F. G.
Right arrow Articles by Reardon, M. J.
PubMed
Right arrow Articles by Bakaeen, F. G.
Right arrow Articles by Reardon, M. J.
Related Collections
Right arrow Cardiac - other

J Thorac Cardiovasc Surg 2009;137:1454-1460
© 2009 The American Association for Thoracic Surgery

Acquired Cardiovascular Disease

Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era

Faisal G. Bakaeen, MDa,*, Dawn E. Jaroszewski, MDa,b, David C. Rice, MDb, Garret L. Walsh, MDb, Ara A. Vaporciyan, MDb, Steven S. Swisher, MDb, Robert Benjamin, MDb, Shanda Blackmon, MDb,c, Michael J. Reardon, MDb,c

a Baylor College of Medicine, Houston, Tex
b M. D. Anderson Cancer Center, Houston, Tex
c Methodist DeBakey Heart and Vascular Center, Houston, Tex

Received for publication August 11, 2008; revisions received October 28, 2008; accepted for publication November 18, 2008.

* Address for reprints: Faisal G. Bakaeen, MD, Department of Cardiothoracic Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030. (Email: fbakaeen{at}bcm.edu).

Objective: Primary cardiac sarcomas are rare tumors carrying poor prognosis. Resection remains the primary therapy. Especially in recent years, chemotherapy and radiation have been used adjunctively.

Methods: All patients (n = 27) surgically treated for primary cardiac sarcoma at two tertiary referral centers from January 1990 to January 2006 were retrospectively reviewed.

Results: There were 13 women and 14 men, with 26 resections and 1 palliative debulking performed. Cardiac explantation was necessary in 8 cases because of tumor location. Concomitant valve surgery (repair or replacement) or coronary artery bypass grafting was performed in 9 and 3 patients, respectively. Synchronous or staged resections of associated pulmonary metastases were performed in 6 and 2 patients, respectively. Operative mortality was 7.4% (2/27). Preoperative or postoperative chemotherapy was administered to 16 and 19 patients, respectively. At follow-up (median 22 months, range, 2–119 months), 12 patients were alive, with 7 tumor free. Among patients who underwent resection with curative intent and survived surgery (n = 24), median survival was 23.5 months (range 4–119 months). Patients who underwent surgical resection, radiofrequency ablation, or radiation treatment for tumor recurrence (local or metastatic, n = 7) had median survival of 47 months (range 16–119 months), whereas patients with no further intervention for recurrent disease (n = 7) had median survival of 25 months (range 8–34 months).

Conclusions: Multimodal therapy can achieve reasonable survival for patients with resected cardiac sarcomas. Patients with local tumor recurrence or metastatic disease may still benefit from aggressive treatment.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.